Microfluidic-based prostate cancer model for investigating the secretion of prostate-specific antigen and microRNAs in vitro

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
Microfluidic-based prostate cancer model for investigating the secretion of prostate-specific antigen and microRNAs in vitro ; volume:13 ; number:1 ; day:19 ; month:7 ; year:2023 ; pages:1-12 ; date:12.2023
Scientific reports ; 13, Heft 1 (19.7.2023), 1-12, 12.2023

Creator
Padmyastuti, Adventina
Sarmiento, Marina Garcia
Dib, Maria
Ehrhardt, Jens
Schoon, Janosch
Somova, Maryna
Burchardt, Martin
Roennau, Cindy
Pinto, Pedro Caetano
Contributor
SpringerLink (Online service)

DOI
10.1038/s41598-023-38834-y
URN
urn:nbn:de:101:1-2023102512463593820543
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:53 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Padmyastuti, Adventina
  • Sarmiento, Marina Garcia
  • Dib, Maria
  • Ehrhardt, Jens
  • Schoon, Janosch
  • Somova, Maryna
  • Burchardt, Martin
  • Roennau, Cindy
  • Pinto, Pedro Caetano
  • SpringerLink (Online service)

Other Objects (12)

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy

Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Prostate-specific antigen-based screening: controversy and guidelines

Prostate-specific antigen-based screening: controversy and guidelines

Prostate-specific antigen testing accuracy in community practice

Prostate-specific antigen testing accuracy in community practice

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery

Related objects